Sexual Health


Introducing Verrutop For Sexual Health

Verrutop has been regularly used in a number of European settings for several years and whilst much of the published clinical data spans all aspects of HPV wart therapy from a dermatological perspective there have been a number of standalone reports looking specifically at ano-genital warts which bolster the specific use of Verrutop in this field.

The most recent study, a single blinded RCT post-dates the publication of the EADV Position document.

Verrutop has an impressive and increasing range of clinical studies to support its introduction.

JEADV

Verrutop: included in recent Position Statement

Treatment: Nitric–zinc complex topical solution

Mode of action: Induces a caustic effect on the wart through mummification and protein denaturation/coagulation action

Schedule: Once or up to four times; repeat at 2-week intervals if needed

Clearance rate (%): 90–99

Recurrence rate (%): Not evaluated

Advantages: Efficacy, Easy application

Disadvantages: Current evidence in AGW available from a limited number of patients only, Investigation of recurrence rate is required


Clinical Papers

Verrutop
Verrutop
Verrutop

Call Us

 

For more information or to arrange a face to face meeting (or virtual meeting) please call us on 01462 346100 or email chris@esperehealth.co.uk

To Order

Verrutop 4x0.1ml ampoule pack can be ordered directly from Espère Healthcare Ltd by calling us on 01462 346100 and we will deliver within 24-48 hours.

Alternatively, Verrutop is listed under the NHS Supply Chain Sexual Health Framework using NPC code FPH053

Verrutop Data

Verrutop – changing the management of genital warts – a little drop at a time